Motzer RJ, et al. - Researchers performed a phase III trial including patients with locally advanced renal cell carcinoma (RCC) at high risk for relapse after nephrectomy to assess the efficacy and safety of pazopanib vs placebo. As per the primary disease-free survival analysis, pazopanib 600 mg demonstrated no benefit over placebo in the adjuvant setting.